Wayde McMillan: Hi, Larry. So for our margins, as you mentioned, we stepped them down this quarter for both some micro and macro issues. You know I think as has been well publicized across many companies, the macro environment is tough, both from an inflationary and foreign exchange, and we’ve felt that as well. We also have a couple of things that impacted us in the quarter. You saw us talk about our warranty increase on our PDMs as well as some of the volume that we’re increasing in our Acton facility. And then just a highlight for folks. You saw us take down our gross margin guidance for drug delivery. That’s a higher margin product line. And so when we reduce revenue guidance there, that’s a headwind for us. And then we’ve increased our volume for Omnipod 5. Our expectations for Omnipod 5 are growing even above what we originally thought. And cost of goods sold are slightly higher for Omnipod 5 as well. So, although that’s a good thing that we’re growing volumes with Omnipod 5, it is a headwind to our cost of goods sold. So that creates about a 2% impact to gross margins, and that really is what drops through to operating margins. We also have other inflationary headwinds throughout operating expenses, given the wage environment as well as services and other increased costs out there that most companies are dealing with. So that’s the reason that we changed our guidance. It’s a little too early to tell what expectations will be beyond 2022, we have to monitor closely the macro environment here. What we do know is that, we are paying higher cost for inputs, raw materials and components to build capacity. And you can see it in our inventory as we continue to grow inventory, our operations teams are doing a great job of identifying capacity and growing inventory in this environment, but it is coming at a higher cost. And with the inventory that we’ve built, a lot of that is deferred over a six-month period of time. And so that’s already starting to impact what our gross margins will be next year. So, although we’re very happy to be building inventory and developing extra capacity, it does come at a higher cost. And so that’s going to impact us for some time. But we’re not going to look out beyond that at this point, Larry. I think we’ve got to monitor the macro environment and see what it looks like. What we are going to commit to is that over time, we will continue to expand gross margins and operating margins, that’s a key focus for us. It may not be in any particular year, especially with the macro headwinds that we’re dealing with today. But you can count on us to continue to expand margins over time.
Wayde McMillan: Yeah. Hi, Travis, it’s glad you asked this question, we get to provide a little more color here. So first of all, you called out the $7 million of channel inventory build, and that’s something that you have to factor into the first half, second half as you’re thinking about the guidance. The other thing to normalize for is, we had an incredibly strong Q4 last year, and so that creates a tough comp for us. So if you include normalization for the channel build, and think about the tough comp, the second half is actually a stronger percentage growth rate and certainly on an absolute dollar basis, a much higher than the first half. So we’ve got a really strong US guide into the second half of the year. And on the channel inventory build, we don’t factor in any major channel build into our guidance. You know we do factor some trends and some normal order patterns and some normal stocking. But whenever we see a large material or significant channel build or channel destock, we call them out, just like we have in the past. And so as we talked about in the prepared remarks here, we’re going to continue to see Omnipod 5 inventory ramp. That will be offset by reductions of our classic Omnipod and Omnipod DASH at our distributors. And depending on how that matches up or is mismatched, it could result in an inventory channel build. And so again, when we see it material, we’ll factor that in and let you guys know in our prepared remarks. But from here, we typically don’t build in large stocking or destocking into our guidance.
Wayde McMillan: Hey, Chris, I’ll start it, and I’ll pass it over to Bret on the questions on Omnipod 5. So regarding SG&A, you may have caught it in the prepared remarks, we talked about increasing our investment in direct-to-consumer advertising on the front end of Omnipod 5, and we certainly have a lot of investment for Omnipod 5, both here in the US as we prepared for the full market release and worked our way through the limited market release. And then internationally, we’ve got a significant amount of work going across many functions, marketing, and in particular, in IT, and we’ve got a significant amount of work to do country-by-country from the infrastructure that needs to be built to support our cloud infrastructure and what we have you know to bring with our Omnipod 5 system is really this differentiated system that works in the cloud and brings a lot of benefits to both the HCPs and the customers. And so we’re working on that. It’s different in every country outside the US. We have to be aware of the privacy laws and other things. So, a lot of investment there, and that’s what you’re seeing show up in our SG&A today. And I’ll pass it over to Bret on Omnipod 5.
Wayde McMillan: Sure, Jayson, it’s Wayde. I can take that one. And this is what we’ve seen historically as well. So we do get this question from time to time. It’s typically when we see that sequential down. And it’s certainly an understandable question, because it’s an annuity model. But what we see happening across our international business, and this is the case in prior years as well. Because we sell a lot of our revenue through the distribution channel, we have ebbs and flows in the distributor inventory patterns and order patterns and depends at the end and beginning of quarters where we’re at and fulfilling those orders. So, it lends itself to be a little bit more difficult to understand, because it is an annuity model. But that’s it. You’ve also seen us call out internationally, whenever we’ve had stocking or destocking of a material nature, you’ve seen us call that out as well. So when we don’t, and we see a couple of million dollar swings between the quarters, it’s really just an order trend and nothing that we’re concerned about or I think we should be calling out as well. And as we move into the second half of the year, you’re right, Q3 goes up, but we typically see a seasonal decline in Q4 as well. And that’s some of the distributors, I think, managing their inventory at the calendar year end. And so, really nothing to talk about here, Jayson, other than just some normal inventory trends. And you know again, we’ll call it out when we see anything material.
Wayde McMillan: Yeah, Matt. I’m not sure I quite followed all that math. But I think if I followed you right, what you’re saying is you know first half, you know strong growth rates. And if you do normalize for that $7 million channel inventory build, we have about a 26% growth rate in the US in Q2. And so, then you take that and you look at the second half guide, where, as you said, we’re in the mid-20s, and that’s a strong guide for us, especially given that tough competitive comp we have in Q4 of last year was such a strong quarter. And then, where is the growth going to come from? It’s all the above, Matt. It’s pretty exciting. As you know, all of the drivers that we’ve had in the business before Omnipod 5 are really what are continuing to drive the business here. The pay-as-you-go model, the DASH product itself, all the economic benefits that Bret just mentioned. And so, as well as the differentiated opportunity we have in Type 2 in the pharmacy channel. So, a lot of drivers, and that is going to be what continues to drive the business. And then Omnipod 5 at 25% of the new customer starts here in Q2 will continue to be a driver as that continues to ramp. So, you know we’ve got a lot of growth momentum in the US, and I think the guidance reflects that.
Wayde McMillan: Sure. Hey, Jeff, I was a little disappointed actually if you weren’t going to be on. So it was great to hear your voice. And I’ll just answer the first part really quickly. The $7 million is net. So that is the net impact of Omnipod 5 inventory ramping and classic Omnipod and DASH coming down.
Jim Hollingshead: Thanks, Robbie. Thanks for the congratulations, too. I think it’s a little bit early to say about how the rates are going to settle out. We’re very happy with adoption of Omnipod 5 across the board. As we said, you know more than 80% of our new customer starts are patients coming from MDI, and so – you know that’s our target market. We are seeing a high percentage of patients converting from Omnipod DASH. And you know to me, that’s a great sign of demand, because what it shows is that, patients who are already on the Omnipod experience, we know they’ve been waiting for Omnipod 5. And so we’re actually, I think, getting a somewhat higher percentage of conversions already. And if you remember, during limited market release, what we’ve been telling the market is the fastest way to get an Omnipod 5 is to get an Omnipod DASH and then convert. So we’re seeing that very well. And we are seeing conversions from other tubed pump offerings. And so we’re getting a mix across the board, and we’re really happy with that.
Jim Hollingshead: Thanks, Steve. On the Type 2 program, we’ve launched – obviously, we have first [technical difficulty] 2 patients very successfully with Omnipod DASH, where we have an indication for use. And as we said in our prepared comments, we had roughly 30% of our new customer starts where people with Type 2 diabetes, and we continue to grow that year-over-year. So we’re very confident that we have a great experience for people with Type 2 diabetes already, fantastic form factor, great pay-as-you-go model and access to the pharmacy, all of which are differentiated. But we are working on Type 2 pipeline. And as you know, we published fantastic feasibility data with Omnipod 5 for patients with Type 2. We published that earlier in the year at ATTD in Barcelona. And based on that study, we’re in conversation with the FDA about the protocol for a pivotal trial. And as we get closer on that, we’ll tell the market more about it. And I’m going to turn to Deb to talk about the randomized controlled trial.
Jim Hollingshead: I’ll just tag on the back of that, Bret, that one thing to bear in mind is, you know as we launch Omnipod 5 and we go market-by-market, with all of that work we’re doing to pioneer the cloud-based offerings, we’re also digging a huge moat. We’re going to do it sequentially. We’re going to do it right and we’re going to do it to win. It will be very difficult for anybody to follow.
Jim Hollingshead: Jeff, thanks for your question. And I actually love your question. And it’s – by the way, it’s great to be here on my first quarter, and I’m loving this, and we have a great team and a great strategy, and we have incredibly talented people and so much passion. But an answer to your question, I don’t think you should think of me as somebody who’s going to you know, cost be damned. We have massive growth opportunities in front of us. You know our investment thesis remains the same, which is, we’re going to drive Omnipod 5. We’re going to drive successful launch and successful growth with Omnipod 5. We’re going to continue to drive international growth with DASH. We’re going to continue to drive Type 2 growth with DASH. And we’re going to fund all of our great innovations that are coming to market, but we’re going to be very prudent with cost and how we do that. You know, we’re obviously in a macro environment that presents a lot of challenges. We are not immune to that. You know that’s happening across industries, it’s happening in our industry. So we’re going to be very prudent with costs and we’re very mindful of that. But we have fantastic growth in front of us, and we’re going to capture it.
Jim Hollingshead: Thanks, Dilem, and thanks, everyone for joining us today. We’ve made terrific progress in the second quarter, and we’re on track for another successful year, despite having to navigate through the challenging macro environment. The full market release of Omnipod 5 is an exciting milestone, and we’re really thrilled to be in full market release with that offering. And our goal is to drive that growth and to finish the year strong and sustain our growth for the long-term. I’ve been really inspired – just on a personal note, I’ve been truly inspired in my first two months here as CEO. We’re making great progress. We are changing people’s lives. We’ve got great and talented people. We have one of the best management teams in MedTech, and we’ve got phenomenal offerings. Insulet has never been in a better position to deliver on our mission to simplify and improve the lives of people at diabetes. Thanks, everyone, and have a great day.
Bret Christensen: Hey, Robbie, it’s Bret. Just to draft in here a little bit. You asked about the exit rate. So yeah, good pickup there. 25% was our mix for the entire quarter. So remember, we just entered a full market release. And so as you can imagine, the ramp throughout the quarter, really the exit rate was quite a bit higher than 25%. So, we’re in a great spot going into Q3, you should expect that Q3 is going to be a much higher mix of our new starts as Omnipod 5. The other thing to remember is, I know many of you look at IQVIA data to sort of understand what new starts are, there’s a component there called NRx, which is usually a really good way to take a look at new prescriptions on a product. For Omnipod 5, it’s pretty high. And there’s just some things to keep in mind there. One, Jim called out the percent of conversion. So we have a very large percentage of new to Omnipod 5 that are conversions from our legacy products. The other thing to remember is that, Omnipod 5 requires two prescriptions. So it requires a prescription for a starter kit and a refill of pods. And so, as you look at the IQVIA data, you’re just going to want to make sure that you’re only viewing one of those. And that you remember that, the majority of new to Omnipod is conversions. But we’re thrilled to be in full market release, and the team is excited to just be – in full promotion mode starting Q3.
Bret Christensen: Yeah. Hi, Chris. The pricing of Omnipod 5 versus DASH, remember, we said we would price it at parity to DASH, and we’re sticking to that. So we are offering payers the exact same rebates for Omnipod 5 that we offered for DASH. The exception to that – and the reason you might see some discrepancies in pricing are mainly around mix. And remember, Omnipod 5 is a pharmacy-only product. So we did have a few payers that were in DME that we are not offering Omnipod 5 in DME and so they do have to move to the pharmacy channel. So that will cause you know a little bit of price lift, frankly, in the pharmacy channel for the average pod pricing, but per payer, there’s pricing at parity with just a few exceptions.
Bret Christensen: Yeah, Joanne, this is Bret. Yeah, you know most of the learnings from the US, we can translate to a European launch. And so remember, there’s a lot to learn from Omnipod 5. It’s – there’s self-service, there’s different training. We’ve learned a lot with training and support in coordination with Dexcom, our CGM partner. So all of those will serve us well when we launch in Europe. There’s still work to do. And Jim mentioned, you know we are well on our way to CE Mark in Europe. And we’ve still got work to do even after CE Mark. So, you know we are targeting middle of ‘23 for the first markets in Europe to come on board, and that will – that effort will move into ‘24, because they are going to be staggered launches. So there’s work to do with the cloud. And remember, we’re pioneering here. You know, we are going to be the first company that’s getting real-time data on every single user. So we’re putting a SIM card in PDMs. We’re building a cloud that meets the requirements of every country. And then we’re assessing the reimbursement environment. We’ve got to establish reimbursement for an AID system that is Omnipod, and we’re looking at the potential for different pricing in those markets. So, all-in-all, there’s work to be done even after CE Mark, and you can expect those launches to come in a staggered fashion starting in the middle of ‘23.
Bret Christensen: Yeah, Cecilia, this is Bret. So you know the list is long of what we learned in the LMR. And you know we’re thrilled again to be moving to full market release. But we commented on some of what we’ve learned. A lot has to do with the onboarding experience. We adjusted the trading protocols, some of the self-service options, some of the expectation setting for those that might be coming from an AID system versus MDI, there’s a lot to learn there, and we got really comfortable with that, which is why we’re moving to full market release.
Bret Christensen: The free trials. Certainly, yes. So, the 10-days is a great question, because we are committed to free trial with Omnipod 5, and you know it was a 30-day free trial with DASH. And while we wanted to do that same trial with Omnipod 5, Omnipod 5 is a system that includes the Dexcom, CGM. So, that was really in coordination with our partner there and Dexcom, as they offer a free 10-day trial, we want to make sure that we’re not offering a trial that doesn’t include a CGM. So a lot of work there and a lot of coordination that went into that, but we’re committed to doing free trials for Omnipod 5, and it’s something you will see us continue to offer.
Bret Christensen: Yeah. Margaret, I mean, it’s – you know this inventory build is almost something that’s just unavoidable with a product launch like Omnipod 5. I mean, ideally, you’d love to see the DASH inventory drop at the same rate that Omnipod 5 is going up. But look, we try to project this as well as we can and communicate with our distributors. And I think it’s fair to say demand just exceeded our expectations here, you know especially with conversions. So the one thing we have to point to was when we launched DASH, we did see conversions from our legacy product, but demand for Omnipod 5 is just much different. And we have podders who have been waiting for Omnipod 5 for a long time. And that is – you know we just saw a lot more conversions, a lot more demand, and that resulted in a little bit of inventory build. But again, it’s healthy, and we try to keep it to a minimum.
Bret Christensen: Hi, Josh, it’s Bret, Brian, sorry. We think cost is very important. And it’s one of the reasons why years ago, we decided to move to the pharmacy channel, more importantly, move to a pay-as-you-go model, because it is – the upfront fee is very disruptive and very difficult for patients, especially if they have not met their deductibles. So you know for us, we don’t see these type of headwinds and these fluctuations, because the co-pays in the pharmacy are predictable and they’re low. And remember, the majority – the vast majority of our patients pay something less than $50. So the average is much lower than that. And as Jim said, many pay zero. So you know the pay-as-you-go model is really important. We topped that off with free trial, you know and you can try Omnipod for free, if you want to. And then, I think the final part of your question is about lowering co-pays, and that’s just an effort we’re always making. And we talk about that as functional access. So we want to do a few things. We want to remove prior offs. We want to remove high co-pays. And in some cases, we’re willing to give up a little bit on the rebate percentage with payers if we can get that accomplished, because we want to remove every obstacle we can to get it on Omnipod.
